Biopharmaceutical Third-party Logistics Market Size, Share and Growth Outlook, 2026

Biopharmaceutical Third-party Logistics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biopharmaceutical Third-party Logistics Market size is forecast to increase from $172.2 Billion in 2026 to $278.63 Billion in 2034 at a CAGR of 6.2% between 2026 and 2034.

The Biopharmaceutical Third-party Logistics market report provides detailed analysis and outlook of Biopharmaceutical Third-party Logistics segments including By Supply Chain Category (Cold Chain Logistics, Non-Cold Chain ), By Service Type (Transportation Services, Warehousing and Storage Services, Packaging and Thermal Consolidation Services, Value-Added Services), By Mode of Transportation (Air Freight, Overland, Sea, Rail Freight), By Product Type (Specialty Drugs and Biologics, Biosimilars and Biobetters, Clinical Trial Materials, Plasma-Derived Products, Cell and Gene Therapies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biopharmaceutical Third-Party Logistics (3PL) Industry Overview

Specialized Cold Chain Infrastructure Is Becoming Central to Biopharmaceutical Distribution

The biopharmaceutical third-party logistics industry is undergoing rapid expansion as pharmaceutical manufacturers increasingly rely on specialized logistics providers to manage complex global supply chains. Growth in biologics, cell and gene therapies, vaccines, and temperature-sensitive pharmaceutical products is creating demand for highly controlled transportation and storage environments. Modern biopharmaceutical logistics operations require strict adherence to regulatory standards, temperature integrity, product traceability, and real-time monitoring capabilities. As advanced therapies become more prevalent, logistics providers are investing heavily in specialized infrastructure designed to ensure product quality and uninterrupted supply throughout the distribution process.

Strategic Acquisitions and Infrastructure Investments Strengthening Global Networks

Industry participants are expanding their healthcare logistics capabilities through acquisitions and large-scale infrastructure development. United Parcel Service strengthened its healthcare logistics presence through the acquisition of Andlauer Healthcare Group for approximately USD $1.6 billion. The transaction adds specialized cold-chain capabilities, multi-temperature transportation networks, and healthcare-focused distribution infrastructure to the UPS Healthcare platform across North America. Similarly, DHL Group has accelerated its life sciences and healthcare expansion through a €500 million investment program across the Asia-Pacific region. A key component of this initiative is the deployment of the Singapore Pharma Hub, a €10 million facility featuring 8,200 square meters of GDP- and GMP-compliant storage and distribution environments dedicated to both frozen and ambient-temperature biologics. These investments reflect the increasing importance of global cold-chain capacity as pharmaceutical supply chains become more complex and geographically diverse.

AI-Powered Visibility and Real-Time Monitoring Enhancing Supply Chain Reliability

Technological innovation is becoming a defining characteristic of the biopharmaceutical 3PL market. The growing volume of cell therapies, gene therapies, and time-sensitive vaccines has increased the need for real-time supply chain intelligence and rapid intervention capabilities. FedEx's launch of FedEx Surround exemplifies this trend by integrating Internet of Things sensor networks with artificial intelligence-based predictive tracking tools. The platform provides near real-time shipment visibility and enables immediate response to temperature excursions or environmental deviations that could compromise product integrity. As high-value biologics and personalized therapies require increasingly stringent handling conditions, logistics providers are adopting AI-driven monitoring systems, predictive analytics, and connected cold-chain technologies to improve risk management, maintain regulatory compliance, and ensure reliable delivery of sensitive biopharmaceutical products across global healthcare markets.

Biopharmaceutical Third-party Logistics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biopharmaceutical Third-party Logistics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- DHL Supply Chain & Global Forwarding, Kuehne + Nagel International AG, UPS Healthcare, FedEx Logistics, Cencora, DB Schenker, Cardinal Health, Agility Logistics, SF Express (SF Pharma), Kerry Logistics. The Biopharmaceutical Third-party Logistics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biopharmaceutical Third-party Logistics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biopharmaceutical Third-party Logistics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biopharmaceutical Third-party Logistics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biopharmaceutical Third-party Logistics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biopharmaceutical Third-party Logistics Market Competitive Benchmarking and Company Analysis

Leading companies in Biopharmaceutical Third-party Logistics industry include- DHL Supply Chain & Global Forwarding, Kuehne + Nagel International AG, UPS Healthcare, FedEx Logistics, Cencora, DB Schenker, Cardinal Health, Agility Logistics, SF Express (SF Pharma), Kerry Logistics. The Biopharmaceutical Third-party Logistics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biopharmaceutical Third-party Logistics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biopharmaceutical Third-party Logistics market remains one of the strongest-performing segments in the country.
The US Biopharmaceutical Third-party Logistics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biopharmaceutical Third-party Logistics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biopharmaceutical Third-party Logistics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biopharmaceutical Third-party Logistics markets

Canada's strong Biopharmaceutical Third-party Logistics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biopharmaceutical Third-party Logistics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biopharmaceutical Third-party Logistics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biopharmaceutical Third-party Logistics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biopharmaceutical Third-party Logistics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biopharmaceutical Third-party Logistics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biopharmaceutical Third-party Logistics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biopharmaceutical Third-party Logistics sales through 2034

France Biopharmaceutical Third-party Logistics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biopharmaceutical Third-party Logistics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biopharmaceutical Third-party Logistics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biopharmaceutical Third-party Logistics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biopharmaceutical Third-party Logistics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biopharmaceutical Third-party Logistics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biopharmaceutical Third-party Logistics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biopharmaceutical Third-party Logistics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biopharmaceutical Third-party Logistics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biopharmaceutical Third-party Logistics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biopharmaceutical Third-party Logistics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biopharmaceutical Third-party Logistics Market Segmentation

By Supply Chain Category
Cold Chain Logistics
Non-Cold Chain
By Service Type
Transportation Services
Warehousing and Storage Services
Packaging and Thermal Consolidation Services
Value-Added Services
By Mode of Transportation
Air Freight
Overland
Sea
Rail Freight
By Product Type
Specialty Drugs and Biologics
Biosimilars and Biobetters
Clinical Trial Materials
Plasma-Derived Products
Cell and Gene Therapies

Top Companies in Biopharmaceutical Third-party Logistics Industry

DHL Supply Chain & Global Forwarding
Kuehne + Nagel International AG
UPS Healthcare
FedEx Logistics
Cencora
DB Schenker
Cardinal Health
Agility Logistics
SF Express (SF Pharma)
Kerry Logistics

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025